Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism's known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.

Original publication




Journal article


Emerg Infect Dis

Publication Date





Burkholderia pseudomallei, Steering Group on Melioidosis Vaccine Development, Whitmore’s disease, aerosol inhalation, antimicrobial drugs, bacteria, challenge dose, intranasal, intraperitoneal, intravenous, melioidosis, prevention, vaccine, Animals, Bacterial Vaccines, Burkholderia pseudomallei, Capital Financing, Disease Models, Animal, Humans, Melioidosis, Mice